European Thyroid Journal · 2018 · 15 citations · 25 references
MedicineOncologyPathologyMolecular OncologyMolecular PathologyNeoplasiaNext-generation Sequencing In OncologyOncogene MutationsThyroid CancerThyroid DisordersThyroid EndocrinologyThyroid Nodule EvaluationBraf V600 MutationsBraf V600e MutationPapillary Thyroid Carcinoma PathologyPartial ThyroidectomySomatic Mutation ProfilingThyroglobulin AntibodiesThyroid Cancer PathologyThyroid Nodule Histopathologic Correlation
Background: BRAFV600E (c.1799T>A) somatic mutation evaluation in fine needle aspiration biopsies (FNAB) is a powerful diagnostic tool in the settings of papillary thyroid cancer (PTC). However, its prognostic value is still a matter of great debate and has been addressed mostly in retrospective studies. Objectives: To evaluate whether the somatic BRAFV600E mutation, assessed by direct sequencing in FNAB material of thyroid nodules, may correlate with disease persistence in PTC patients. Study Design: We conducted a prospective cohort study investigating 160 PTC patients previously assessed for the somatic BRAFV600E mutation, and submitted to total thyroidectomy, with a follow-up of 2–10 years. Patients were matched according to somatic BRAFV600E mutation (80 BRAF+ and 80 BRAF– patients) and to the presence (LN+, 40 patients each group) or absence (LN, 40 patients each group) of neck lymphnode metastases. Disease persistence was considered according to basal or TSH-stimulated Thyroglobulin (TG) levels, anti-TG antibodies, neck ultrasound, CT scan where applicable and whole body scan after radioiodine ablation treatment (RAI). Results: The presence of the somatic BRAFV600E mutation did not influence the indication for RAI. None of the enrolled patients showed disease recurrence or died due to disease-related causes. During follow-up, disease persistence did not correlate with the presence of somatic BRAFV600E mutation both in patients submitted to RAI nor in those treated more conservatively. Conclusions: The somatic BRAFV600E mutation does not associate with a worse prognosis in low risk PTC and, in our settings, may not be considered an independent risk factor for disease persistence.
25
Acute Abdomen: A Rare Case of Ruptured Hepatocellular Carcinoma
Severin Gloor, Kai Oliver Jensen, Stefan Breitenstein et al. · Case Reports in Gastroenterology · 2017 · 5.4K citations · Full text
Integrated Genomic Characterization of Papillary Thyroid Carcinoma
Nishant Agrawal, Rehan Akbani, Bülent Arman Aksoy et al. · Cell · 2014 · 3.1K citations · Full text
Papillary thyroid microcarcinoma: A study of 900 cases observed in a 60-year period
Ian D. Hay, Maeve E. Hutchinson, Tomas Gonzalez‐Losada et al. · Surgery · 2008 · 942 citations